Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
ApexOnco Front Page
Recent articles
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
The same trial that sent Summit up 272% sees the stock crash 36%.
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
